Rigosertib

From Food & Medicine Encyclopedia

Chemical Compound
Identifiers
CAS Number
PubChem CID
ChemSpider ID
UNII
ChEBI
ChEMBL
Properties
Chemical Formula
Molar Mass
Appearance
Density
Melting Point
Boiling Point
Hazards
GHS Pictograms [[File:|50px]]
GHS Signal Word
GHS Hazard Statements
NFPA 704 [[File:|50px]]
References

Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.<ref>

Onconova Therapeutics(link). {{{website}}}.


Accessed 2019-04-26.


</ref> Riosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.<ref>https://clinicaltrials.gov/ct2/show/NCT01928537</ref>

Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.

Mechanism[edit]

Rigosertib is a microtubule-destabilizing agent.<ref>,

 Combined CRISPRi/a-Based Chemical Genetic Screens Reveal that Rigosertib Is a Microtubule-Destabilizing Agent, 
 Molecular Cell, 
 2017,
 Vol. 68(Issue: 1),
 pp. 210–223.e6,
 DOI: 10.1016/j.molcel.2017.09.012,
 PMID: 28985505,
 PMC: 5640507,
 
 Full text,</ref>

References[edit]


Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.